THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
MASS. MOVERS

Biogen Idec drug gets European approval

Biogen Idec also makes the multiple sclerosis drug Tysabri. Biogen Idec also makes the multiple sclerosis drug Tysabri. (Biogen Idec Inc. via Bloomberg News)
July 26, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec said it received conditional regulatory approval in Europe to market Fampyra, a treatment to improve walking in patients with multiple sclerosis. The European Commission approved the company’s tablet based on studies showing it increased walking speed up to 25 percent in adults with MS. The approval is conditional and regulators are requiring the company to conduct a long-term, follow-up study of the drug’s benefits. The approval will have to be renewed annually until full approval is granted.